ABCL is trading 4.8% down at $7.32 as the stock extends a multi-day pullback following last week’s sharp oncology-driven rally.
- Recent gains were fueled by optimism around the company's antibody discovery platform and strategic oncology partnerships.
- The current decline appears tied to profit-taking and consolidation rather than new negative company-specific news.